What is the main purpose of this 8-K filing?

This 8-K filing announces that Pfizer Inc. has entered into a definitive merger agreement to acquire Hospira, Inc. It details the key terms of the acquisition, including the purchase price, the structure of the transaction, and the conditions that must be met for the deal to close.

What is the financial consideration for Hospira shareholders?

Hospira shareholders will receive $90.00 in cash for each share of Hospira common stock they own. This cash consideration will be paid without interest.

What are the key conditions for the merger to be completed?

The merger is subject to several conditions, including the approval of the merger by a majority of Hospira's outstanding shares, the expiration or termination of waiting periods under antitrust laws (such as the Hart-Scott-Rodino Act in the U.S. and other international regulations), and the absence of any material adverse effect on Hospira.

Are there any termination clauses or fees associated with this agreement?

Yes, the merger agreement contains specified termination rights for both Pfizer and Hospira. Hospira may be required to pay a significant termination fee to Pfizer under certain circumstances, such as if Hospira terminates the agreement to accept a superior proposal or if its board changes its recommendation. There are also provisions for expense reimbursement.

PFE 8-K: Material Agreements

Summary

Pfizer Inc. announced a significant development on February 5, 2015, with the execution of an Agreement and Plan of Merger to acquire Hospira, Inc. This strategic move involves Pfizer's wholly-owned subsidiary, Perkins Holding Company, merging with and into Hospira. Hospira will continue to exist as a subsidiary of Pfizer following the transaction. The proposed acquisition is structured as an all-cash deal, offering Hospira shareholders $90.00 per share, irrespective of whether the shares are vested or unvested. This acquisition aims to enhance Pfizer's portfolio and market presence. The transaction is subject to customary closing conditions, including the approval from Hospira shareholders and regulatory clearances from antitrust authorities in the U.S. and internationally. Key terms of the merger agreement include provisions for ongoing business conduct, restrictions on soliciting alternative offers, and defined termination rights and fees. Pfizer also highlighted that its projections regarding the accretive impact of the acquisition are based on non-GAAP financial measures, which should be considered alongside GAAP measures.

Key Highlights

1Pfizer Inc. entered into an Agreement and Plan of Merger to acquire Hospira, Inc. on February 5, 2015.
2The acquisition is an all-cash transaction, with Pfizer offering $90.00 per share for Hospira common stock.
3All outstanding Hospira stock options, RSUs, and other equity awards will be converted into the right to receive the per-share merger consideration.
4The merger is contingent upon approval by Hospira shareholders and satisfaction of various antitrust waiting periods, including Hart-Scott-Rodino in the U.S. and international regulatory approvals.
5The merger agreement includes provisions for business conduct, a no-shop clause for Hospira, and specific termination rights and potential termination fees for both parties.
6The transaction has a target termination date of December 31, 2015, with potential extensions under certain conditions.
7Pfizer's projections on the accretive impact of the acquisition are based on non-GAAP financial measures and should be viewed with caution.

PFIZER INC 8-K Report, Material Agreement (Feb 6, 2015)

Summary

Key Highlights

Frequently Asked Questions